Simulations Plus, Inc. (SLP)
| Market Cap | 374.16M +23.4% |
| Revenue (ttm) | 82.06M +2.1% |
| Net Income | 8.11M |
| EPS | 0.40 |
| Shares Out | 20.22M |
| PE Ratio | 46.33 |
| Forward PE | 44.05 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 437,901 |
| Open | 18.50 |
| Previous Close | 18.49 |
| Day's Range | 18.49 - 18.50 |
| 52-Week Range | 11.09 - 21.01 |
| Beta | 1.31 |
| Analysts | Hold |
| Price Target | 17.25 (-6.76%) |
| Earnings Date | Jul 9, 2026 |
About SLP
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for SLP stock is "Hold." The 12-month stock price target is $17.25, which is a decrease of -6.76% from the latest price.
News
Simulations Plus expands FDA adoption of ADMET Predictor in cosmetic safety
Simulations Plus (SLP) announced that the FDA’s Cosmetics Regulatory Science Branch has licensed ADMET Predictor to support its computational research for modern cosmetic safety assessment. The contra...
Simulations Plus Expands FDA Adoption of ADMET Predictor® with New Licenses for the Cosmetics Regulatory Science Branch
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ad...
Simulations Plus Transcript: Status update
ADMET Predictor 14 introduces advanced models and descriptors for beyond rule of five molecules, improving predictions for solubility, permeability, and PK. The new S+ Composer AI front-end automates complex workflows via natural language, while enhanced logging, API, and user interface features boost reproducibility and integration.
Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures
San Diego, California--(Newsfile Corp. - September 15, 2026) - Johnson Fistel, PLLP is investigating Simulations Plus, Inc. (NASDAQ: SLP) for investors who suffered losses and whether they may recover...
Simulations Plus Proxy statement: Proxy filing
Simulations Plus filed a proxy statement on August 21, 2026, providing details for shareholder voting and corporate governance matters.
Simulations Plus Announces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by Altaris
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ad...
Simulation Plus, Inc. Securities Fraud Investigation - Robbins LLP is Investigating Investor Losses in SLP Due to Possible Violations of Securities Laws
San Diego, California--(Newsfile Corp. - July 29, 2026) - Robbins LLP announces that it is investigating Simulation Plus, Inc. (NASDAQ: SLP) to determine whether certain officers and directors violate...
Simulation Plus, Inc. (NASDAQ: SLP) Investors Should Contact Robbins LLP for Information About Investigation
SAN DIEGO--(BUSINESS WIRE)---- $SLP #SimulationPlus--Robbins LLP announces that it is investigating Simulation Plus, Inc. (NASDAQ: SLP) to determine whether certain officers and directors violated sec...
Simulations Plus Proxy statement: Proxy filing
Simulations Plus filed a proxy statement on July 22, 2026, providing details for shareholder voting and corporate governance matters.
Simulations Plus Proxy statement: Proxy filing
Simulations Plus filed a proxy statement on July 20, 2026, providing details for shareholder voting and corporate governance matters.
Simulations Plus reports Q3 EPS 30c vs. 45c last year
Reports Q3 revenue $21.9M vs. $20.4M last year. “We delivered solid third quarter results, with revenue increasing 7%, highlighted by strength in our services revenue, which grew 20%, while software…
Simulations Plus Reports Third Quarter Fiscal 2026 Financial Results
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ad...
Simulations Plus Earnings release: Q3 2026
Simulations Plus released its Q3 2026 earnings on July 9, 2026, summarizing the period's financial results.
Simulations Plus Slides: Q3 2026
Simulations Plus has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on July 9, 2026.
Simulations Plus Quarterly report: Q3 2026
Simulations Plus has published its Q3 2026 quarterly earnings report on July 9, 2026.
Simulations Plus Proxy statement: Proxy filing
Simulations Plus filed a proxy statement on July 9, 2026, providing details for shareholder voting and corporate governance matters.
Simulations Plus (SLP) Investigation: Investors Who Suffered Losses Encouraged to Contact Johnson Fistel
SAN DIEGO, July 1, 2026 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Simulations Plus, Inc. (NASDAQ: SLP). The investigation conc...
Simulations Plus advances agentic drug development with NVIDIA BioNeMet Agent
Simulations Plus (SLP) announced it is building the agentic layer of Composer using the NVIDIA (NVDA) BioNeMo Agent Toolkit. The initiative expands the companies’ collaboration announced in May 2026, ...
Simulations Plus Transcript: Status update
OBESITYsym, a mechanistic QSP model, predicts weight loss and nausea for various obesity treatments, validated across drugs and dosing regimens. It supports translational predictions, adapts to new mechanisms, is being enhanced with AI, models distinct populations like type 2 diabetes, and is validated against recent clinical trial outcomes.
Simulations Plus Advances Agentic Drug Development with NVIDIA BioNeMo Agent Toolkit
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that he...
Simulations Plus, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – SLP
LOS ANGELES--(BUSINESS WIRE)---- $SLP--Simulations Plus, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – SLP.
Simulations Plus downgraded to Hold from Buy at Craig-Hallum
Craig-Hallum downgraded Simulations Plus (SLP) to Hold from Buy with an $18.50 price target after the company entered into an agreement to be acquired by affiliates of Altaris for $18.50…
Simulations Plus downgraded to Market Perform from Outperform at William Blair
William Blair analyst Max Smock downgraded Simulations Plus (SLP) to Market Perform from Outperform without a price target after the company entered into an agreement to be acquired by affiliates…
Leerink says Certara peer acquisition supports higher multiple
Leerink sees Certara’s (CERT) valuation as overly depressed given what remains a highly profitable entity with multiple long-term growth drivers. This morning’s acquisition of peer Simulations Plus (S...
Simulations Plus trading resumes
09:55 EDT Simulations Plus (SLP) trading resumes